Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
25.42
-0.78 (-2.96%)
Feb 9, 2026, 1:16 PM EST - Market open
Alumis Employees
As of September 30, 2025, Alumis had 223 total employees, including 221 full-time and 2 part-time employees. The number of employees increased by 76 or 51.70% compared to the same quarter last year.
Employees
223
Change
76
Growth
51.70%
Revenue / Employee
$99,197
Profits / Employee
-$1,099,341
Market Cap
3.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 223 | 76 | 51.70% | 221 | 2 |
| Jun 30, 2025 | 227 | 97 | 74.62% | 225 | 2 |
| Mar 31, 2025 | 184 | 75 | 68.81% | 182 | 2 |
| Dec 31, 2024 | 170 | 61 | 55.96% | 168 | 2 |
| Sep 30, 2024 | 147 | 38 | 34.86% | 145 | 2 |
| Jun 30, 2024 | 130 | - | - | 128 | 2 |
| Mar 31, 2024 | 109 | - | - | 107 | 2 |
| Dec 31, 2023 | 109 | - | - | 107 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Apellis Pharmaceuticals | 710 |
| Denali Therapeutics | 517 |
| Arcutis Biotherapeutics | 342 |
| Xenon Pharmaceuticals | 327 |
| Vera Therapeutics | 224 |
| Catalyst Pharmaceuticals | 181 |
| Disc Medicine | 142 |
ALMS News
- 4 days ago - Alumis to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 4 weeks ago - Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 4 weeks ago - Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise - Seeking Alpha
- 4 weeks ago - Alumis Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
- 4 weeks ago - Alumis skin disease drug meets main goal of two late-stage trials - Reuters
- 4 weeks ago - Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program - GlobeNewsWire